JP2007512341A - 神経障害性疼痛の治療に有用なピリジン−４−イルアミン化合物 - Google Patents
神経障害性疼痛の治療に有用なピリジン−４−イルアミン化合物 Download PDFInfo
- Publication number
- JP2007512341A JP2007512341A JP2006541366A JP2006541366A JP2007512341A JP 2007512341 A JP2007512341 A JP 2007512341A JP 2006541366 A JP2006541366 A JP 2006541366A JP 2006541366 A JP2006541366 A JP 2006541366A JP 2007512341 A JP2007512341 A JP 2007512341A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- effective amount
- halo
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- YKORLKMHNGQVSH-UHFFFAOYSA-N CCN(CC)CCCC(C)Nc1c(CCCC2)c2nc2c1CCCC2 Chemical compound CCN(CC)CCCC(C)Nc1c(CCCC2)c2nc2c1CCCC2 YKORLKMHNGQVSH-UHFFFAOYSA-N 0.000 description 1
- OULOHOAQVGYIRU-INIZCTEOSA-N CCN(CC)CCC[C@H](C)Nc(c1c2)c(cccc3)c3nc1ccc2Br Chemical compound CCN(CC)CCC[C@H](C)Nc(c1c2)c(cccc3)c3nc1ccc2Br OULOHOAQVGYIRU-INIZCTEOSA-N 0.000 description 1
- IPGSZBGEYLPOME-UHFFFAOYSA-N Clc1c(CCCC2)c2nc2c1CCCC2 Chemical compound Clc1c(CCCC2)c2nc2c1CCCC2 IPGSZBGEYLPOME-UHFFFAOYSA-N 0.000 description 1
- NTUMKASHRHPKLA-UHFFFAOYSA-N O=C1C(CCCC2)=C2NC2=C1CCCC2 Chemical compound O=C1C(CCCC2)=C2NC2=C1CCCC2 NTUMKASHRHPKLA-UHFFFAOYSA-N 0.000 description 1
- CVEXTAUZJWYDJX-UHFFFAOYSA-N O=C1c2ccccc2NC2=C1CCCC2 Chemical compound O=C1c2ccccc2NC2=C1CCCC2 CVEXTAUZJWYDJX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C07D219/12—Amino-alkylamino radicals attached in position 9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52473403P | 2003-11-21 | 2003-11-21 | |
| PCT/US2004/038669 WO2005051915A1 (en) | 2003-11-21 | 2004-11-18 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007512341A true JP2007512341A (ja) | 2007-05-17 |
| JP2007512341A5 JP2007512341A5 (https=) | 2008-01-10 |
Family
ID=34632928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541366A Withdrawn JP2007512341A (ja) | 2003-11-21 | 2004-11-18 | 神経障害性疼痛の治療に有用なピリジン−４−イルアミン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070099950A1 (https=) |
| EP (1) | EP1687275A4 (https=) |
| JP (1) | JP2007512341A (https=) |
| CN (1) | CN1882546A (https=) |
| AU (1) | AU2004292546A1 (https=) |
| CA (1) | CA2545786A1 (https=) |
| WO (1) | WO2005051915A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| WO2006127329A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Quinoline derivatives useful as modulators of ion channels |
| HRP20201384T1 (hr) | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| EP3646886B1 (en) * | 2017-06-28 | 2023-10-04 | Osaka University | Treatment of pain with serotonin-3 receptor agonist |
| CN107721925B (zh) * | 2017-09-12 | 2020-02-14 | 上海交通大学 | 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用 |
| GB2568291A (en) * | 2017-11-13 | 2019-05-15 | Crisby Milita | New use |
| CN114149410B (zh) * | 2020-09-07 | 2025-02-25 | 四川科伦博泰生物医药股份有限公司 | 吡啶并环类化合物及其制备方法和用途 |
| CN112300071B (zh) * | 2020-11-25 | 2023-01-31 | 威胜生物医药(苏州)股份有限公司 | 一种高纯度磷酸氯喹的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2077249A (en) * | 1934-06-06 | 1937-04-13 | Winthrop Chem Co Inc | Basically substituted acridine compounds |
| US3066141A (en) * | 1957-04-26 | 1962-11-27 | Jr Ralph Jones | Quinoline-type mustards and process for producing same |
| US5021426A (en) * | 1990-02-26 | 1991-06-04 | Merck & Co., Inc. | Method of traeting malaria with cyproheptadine derivatives |
| EP0446604A3 (en) * | 1990-03-16 | 1992-02-19 | American Cyanamid Company | Pyridine and related aza heterocycle derivatives as cardiovascular agents |
| FR2676228B1 (fr) * | 1991-05-07 | 1995-01-06 | Rhone Poulenc Chimie | Procede de preparation de sulfate de chloroquine. |
| WO1996039818A1 (en) * | 1995-06-07 | 1996-12-19 | Cerus Corporation | Treating red blood cell solutions with anti-viral agents |
| US5783584A (en) * | 1995-12-11 | 1998-07-21 | Mayo Foundation For Medical Education And Research | THA analogs useful as cholinesterase inhibitors |
| AU1290700A (en) * | 1998-12-02 | 2000-06-19 | Pfizer Products Inc. | Methods and compositions for restoring conformational stability of a protein of the p53 family |
| US6194403B1 (en) * | 1999-09-09 | 2001-02-27 | Unitech Pharmaceuticals, Inc. | Tacrine derivatives for treating Alzheimer's disease |
-
2004
- 2004-11-18 WO PCT/US2004/038669 patent/WO2005051915A1/en not_active Ceased
- 2004-11-18 CN CNA2004800341960A patent/CN1882546A/zh active Pending
- 2004-11-18 US US10/580,393 patent/US20070099950A1/en not_active Abandoned
- 2004-11-18 EP EP04811391A patent/EP1687275A4/en not_active Withdrawn
- 2004-11-18 CA CA002545786A patent/CA2545786A1/en not_active Abandoned
- 2004-11-18 AU AU2004292546A patent/AU2004292546A1/en not_active Abandoned
- 2004-11-18 JP JP2006541366A patent/JP2007512341A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2545786A1 (en) | 2005-06-09 |
| CN1882546A (zh) | 2006-12-20 |
| AU2004292546A1 (en) | 2005-06-09 |
| EP1687275A4 (en) | 2009-01-14 |
| US20070099950A1 (en) | 2007-05-03 |
| WO2005051915A1 (en) | 2005-06-09 |
| EP1687275A1 (en) | 2006-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104203914B (zh) | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 | |
| EP0356128B1 (en) | 3-(aminopropyl)methyl phosphinic acid as a therapeutic agent | |
| US8829190B2 (en) | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | |
| JP5743901B2 (ja) | 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体 | |
| US20080249154A1 (en) | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | |
| JP2002521436A (ja) | 置換アニリド化合物および方法 | |
| JPWO2005047286A1 (ja) | スピロ複素環化合物 | |
| US20100197721A1 (en) | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | |
| CZ288944B6 (cs) | Derivát 5H-thiazolo[3,2-a]pyrimidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje | |
| JP2005536507A (ja) | ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療 | |
| HUP0204458A2 (hu) | Alfa-2-antagonista hatású kinolinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| JP2003506437A (ja) | 苦痛状態の治療のためのｎｍｄａ−レセプターアンタゴニストとして有効な置換された１，５−ジヒドロピロール−２−オン誘導体 | |
| NZ238141A (en) | 1,2,3,4,4a,10b-hexahydro-6-(sulphonamidophenyl)benzo(c)(1,6)naphthyridine derivatives, preparation and pharmaceutical compositions thereof | |
| US6448259B1 (en) | Substituted cycloalkyl-4-oxonicotinic carboxamides; GABA brain receptor ligands | |
| CA2481855A1 (en) | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | |
| JP2007512341A (ja) | 神経障害性疼痛の治療に有用なピリジン−４−イルアミン化合物 | |
| JP2008515907A (ja) | チエノピリジノン化合物およびその処置方法 | |
| JP2003506436A (ja) | Ｎｍｄａ−レセプターアンタゴニストとしての置換されたピロリジン−２，３，４−トリオン−３−オキシム誘導体 | |
| US10053453B2 (en) | Compounds and their use as BACE inhibitors | |
| JP2001525813A (ja) | ドパミンｄ３受容体のモジュレーターとしての置換テトラヒドロイソキノリン誘導体 | |
| US20080004272A1 (en) | Compositions and methods for modulating gated ion channels | |
| JPH05506012A (ja) | 中枢神経系障害治療用含窒素シクロヘテロシクロアルキルアミノアリール誘導体 | |
| US20140107153A1 (en) | Therapeutic quinoline and naphthalene derivatives | |
| KR20190117658A (ko) | 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법 | |
| TW200846328A (en) | GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071116 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090406 |